Navigation Links
Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis

Columbia, MD (PRWEB) December 17, 2013

Identifying SVP (sub-visible particle) aggregates that can cause severe side effects in biopharmaceuticals has been a longtime concern in the pharmaceutical industry. Shimadzu Scientific Instruments has introduced the Aggregates Sizer Aggregation Analysis System, which offers the first effective quantitative, high-speed evaluation of 100 nm to 10µm SVP aggregates that may be present in biopharmaceuticals.

Generation of aggregates in the sub-visible range can occur during development of biopharmaceuticals because of mechanical stimulation or temperature changes. The Aggregates Sizer is capable of covering all ranges of SVP particle size in a single measurement, and can evaluate the concentration (µg/mL) that can induce allergic systemic reactions such as anaphylaxis and other severe side effects.

The new system offers greater quality control and improved efficiency in the development of biopharmaceuticals. By enabling screening for and elimination of aggregation prone-proteins in the early stages of drug development, Shimadzu’s Aggregates Sizer will save time and reduce costs.

The Aggregates Sizer also features greater sensitivity and speed than previous size analyzers. The instrument is capable of accurately measuring micro sample quantities using disposable cells for 0.4 mL sample quantities. Size and quantity changes can be confirmed quantitatively as a concentration (unit: µg/mL) at one-second intervals, allowing real-time evaluation of rates of change and observation of aggregation processes as samples are mechanically stimulated.

Shimadzu offers a variety of software and system configuration options for a broad range of uses, environments and conditions. For more information, visit .

About Shimadzu Scientific Instruments Inc.
Shimadzu Scientific Instruments (SSI) is the American subsidiary of Shimadzu Corp., headquartered in Kyoto, Japan. Founded in 1875, Shimadzu is a $3 billion multinational corporation with three major divisions: Medical Diagnostics, Aerospace/Industrial and Analytical Instruments. In the United States, SSI has a network of more than 50 locations providing local and regional sales, service and technical support. Visit for more information.

# # #

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Shimadzu’s New Triple Quadrupole LCMS-8050 Mass Spectrometer Offers Combination of Outstanding Sensitivity With Ultra-fast, Accurate Analysis
2. Alacrita Aggregates the Life Science Practices of Two Consulting Firms and Appoints Simon Turner Ph.D FRSC as Partner
3. Peptide Machines, Inc. Introduces New High-Quality, Cost-Efficient, Fully Automated Multiple Peptide Synthesizer with Preactivation
4. Americas Pharmaceutical Market Forecasts to 2018
5. Industry Shares, Size, Trend, Analysis, and Forecasts to 2018 Report Available Online by
6. Global Bulk Molding Compounds Market and China LOW-E Glass Analysis in New Research Added to
7. Monoclonal Antibodies Market in Colorectal Cancer to 2019
8. Industry Shares, Size, Trend, Analysis, and Forecasts Report Available Online by
9. MediPoint: Cardiac Rhythm Management - US Analysis and Market Forecasts
10. PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022
11. Ventana receives FDA clearance for Estrogen Receptor (ER) Image Analysis and Digital Read Application for breast cancer
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):